natgillin/translations-raw huggingface dataset:
De lider af åreforkalkning (også kaldet aterosklerose) - og
You have a condition of hardening of arteries (also known as atherosclerosis), and
De lige numre står på doserings- knappen.
The even numbers are printed on the dial.
De lipidsænkende egenskaber hos fenofibrat, der er set i klinisk praksis, er blevet klarlagt in vivo hos transgene mus og i humane hepatocytkulturer ved aktivering af peroxisom proliferator-aktiveret receptor af alfa-typen (PPARα).
The lipid-lowering properties of fenofibrate seen in clinical practice have been explained in vivo in transgenic mice and in human hepatocyte cultures by activation of Peroxisome Proliferator Activated Receptor type α (PPARα).
De lokale reaktioner forsvinder gradvist, men hos 20-30 % af dyrene kan de vare i mere end 42 dage.
A gradual resolution of the local reactions occurs, but in 20–30% of the animals these may persist for more than 42 days.
de lokale reaktioner spreder sig til resten af din krop
the local reactions spread to other parts of your body
De lægemidler, der anvendes til denne behandling, kan beskadige de celler, der beklæder leverens blodkar indvendigt, hvilket er årsag til de blodpropper, der ses ved VOD.
The medicines used for this treatment can damage the lining of the blood vessels in the liver, leading to the formation of clots and obstruction of the vessels seen in VOD.
De lægemidler, der er uforligelige med med bivalirudin i højere koncentrationer er: Dobutaminhydrochlorid, famotidin, haloperidollactat, labetalolhydrochlorid, lorazepam og promethazin HC1.
The medicinal products incompatible with bivalirudin at higher concentrations are: dobutamine hydrochloride, famotidine, haloperidol lactate, labetalol hydrochloride, lorazepam and promethazine HCl.
De maksimale daglige eksponeringer defineret ved arealet under kurven (AUC) ved koncentrationer, hvor der ikke observeredes bivirkninger (NOAEL), var i 9-måneders-studiet hos hunde 2,3 gange større end AUC hos mennesker efter en subkutan dosis på 30 mg.
Maximum daily exposures defined by area under the curve (AUC) at the No Observed Adverse Effect Levels (NOAEL) in the 9-month study in dog were 2.3 times the AUC in humans after a subcutaneous dose of 30 mg.
De maksimale gennemsnitlige (95% øvre konfidensgrænse) forskelle i QTcF fra placebo var 5,5 (7,6) for 400 mg ritonavir to gange daglig.
The maximum mean (95% upper confidence bound) difference in QTcF from placebo was 5.5 (7.6) for 400 mg twice daily ritonavir.
De maksimale humane plasmakoncentrationer er < 1 ng/ml og opnås inden for < 1 time.
Maximum human plasma concentrations are < 1 ng/mL and achieved within < 1 hour.
De maksimale individuelle plasmakoncentrationer af AUX-I og AUX-II var hhv.
The maximal individual plasma concentrations of AUX-I and AUX-II were
De maksimale koncentrationer af emodepsid og toltrazuril blev nået henholdsvis 2 timer og 18 timer efter behandling.
Maximum concentrations of emodepside and toltrazuril were reached 2 hours and 18 hours after treatment respectively.
De maksimale plasmakoncentrationer af selexipag og dets aktive metabolit efter oral administration nås i løbet af hhv.1-3 timer og 3-4 timer.
Maximum observed plasma concentrations of selexipag and its active metabolite after oral administration are reached within 1–3 h and 3–4 h, respectively.
De maksimale plasmaværdier (4,2+0,9 g/ml) nås omkring 22 timer efter administrationen.
Maximum concentrations in plasma (4.2±0.9 µg/ml) are reached at approximately 22 hours after administration.
De maksimale serumkoncentrationer (Cmax) nås cirka 2,5 timer efter oral indtagelse (gennemsnitligt 0,3 µg/ml ved gentagen dosering af 4 mg daglig).
Maximum serum concentrations (Cmax) are reached approximately 2.5 hours after oral intake (mean 0.3 µg/ml during multiple dosing of 4 mg daily).
De mediane doser administreret i henholdsvis den 3-ugers og den 4-ugers behandlingsplan var næsten ens (428,3 vs.
The median doses administered for the 3-week and 4-week treatment schedules were almost identical to each other (428.3 vs.
De mediane ændringer i QTcF fra baseline var 3,0 msek. hos patienter, der blev behandlet med dasatinib, sammenlignet med 8,2 msek. hos patienter, der blev behandlet med imatinib.
The median changes in QTcF from baseline were 3.0 msec in dasatinib-treated patients compared to 8.2 msec in imatinib-treated patients.
De meest voorkomende bijwerkingen die met Zyllt worden gemeld zijn bloedingen.
The most common side effect is bleeding.
De meget almindelige bivirkninger (kan forekomme hos flere end 1 ud af 10 patienter) er:
Very common side effects (may affect more than 1 in 10 people) are:
De meget almindelige bivirkninger, der sås hos mindst 10 % af de Giotrifbehandlede patienter i LUX- Lung 8-studiet, er opstillet i tabel 4 i henhold til NCI-CTC (National Cancer Institute-Common Toxicity Criteria).
Very common ADRs in GIOTRIF-treated patients occurring in at least 10% of patients in trial LUX-Lung 8 are summarised by National Cancer Institute-Common Toxicity Criteria (NCI-CTC) Grade in Table 4.
De mest almindelige af disse infusionsrelaterede reaktioner omfattede kutane reaktioner (udslæt, pruritus, urticaria), pyreksi, hovedpine, hypertension og ansigtsrødme.
The most common of these infusion-related reactions included cutaneous reactions (rash, pruritus, urticaria), pyrexia, headache, hypertension and flushing.
De mest almindelige alvorlige bivirkninger (der kan forekomme hos mere end 1 ud af 50 patienter) omfatter diarré, kvalme og opkastning, lavt antal hvide blodlegemer (neutropeni) og feber, blodforgiftning (sepsis) og lungebetændelse, chok, væskemangel, nyresvigt og lavt antal blodplader (trombocytopeni).
The most common serious side effects (which may affect more than 1 in 50 people) included diarrhoea, nausea and vomiting, neutropenia and fever, infections of blood or lungs (sepsis, pneumonia), shock, dehydration, kidney failure and thrombocytopenia (low levels of blood platelets).
De mest almindelige alvorlige bivirkninger (≥ 2%) rapporteret for belatacept i begge doseringsregimer (mere intensiv [MI] og mindre intensiv [LI]) kumulativt op til år 3 var urinvejsinfektion, CMV- infektion, pyreksi, forhøjet blodkreatinin, pyelonefritis, diarre, gastroenteritis, transplantatdysfunktion, leukopeni, pneumoni, basalioma, anæmi, dehydrering.
The most common serious adverse reactions (≥ 2%) reported with belatacept in both regimens (more intensive [MI] and less intensive [LI]) cumulative up to Year 3 were urinary tract infection, CMV infection, pyrexia, increased blood creatinine, pyelonephritis, diarrhoea, gastroenteritis, graft dysfunction, leukopenia, pneumonia, basal cell carcinoma, anaemia, dehydration.
De mest almindelige behandlingssamtidige bivirkninger, der blev indberettet i kliniske studier med voksne epilepsipatienter, i både placebo- og eslicarbazepinacetat-gruppen, var svimmelhed, somnolens, hovedpine og kvalme.
The most common treatment-emergent adverse reactions reported in clinical studies with adult epileptic patients, both in placebo and eslicarbazepine acetate groups were dizziness, somnolence, headache, and nausea.
De mest almindelige behandlingssamtidigebivirkninger, der blev indberettet i kliniske studier med voksne epilepsipatienter, i både placebo- og eslicarbazepinacetat-gruppen, var svimmelhed, somnolens, hovedpine og kvalme.
The most common treatment-emergent adverse reactions reported in clinical studies with adult epileptic patients, both in placebo and eslicarbazepine acetate groups were dizziness, somnolence, headache, and nausea.
De mest almindelige bivirkninger (> 30 %) rapporteret ved behandling med vemurafenib inkluderer artralgi, træthed, udslæt, lysfølsomhedsreaktion, kvalme, alopeci og kløe.
The most common adverse drug reactions (ADR) (> 30%) reported with vemurafenib include arthralgia, fatigue, rash, photosensitivity reaction, nausea, alopecia and pruritus.
De mest almindelige bivirkninger (forekom hos mindst 10 % af patienterne) i RCC- og STS-studierne omfattede: diarré, ændringer i hårfarve, hypopigmentering af huden, eksfoliativt udslæt, hypertension, kvalme, hovedpine, træthed, nedsat appetit, opkastning, dysgeusi, stomatitis, vægttab, smerte samt forhøjet ALAT- og ASAT-niveauer.
The most common adverse reactions (experienced by at least 10 % of the patients) of any grade in the RCC and STS trials included: diarrhoea, hair colour change, skin hypopigmentation, exfoliative rash, hypertension, nausea, headache, fatigue, anorexia, vomiting, dysgeusia, stomatitis, weight decreased, pain, elevated alanine aminotransferase and elevated aspartate aminotransferase.
De mest almindelige bivirkninger (kan forekomme hos op til 1 ud af 10 patienter), er opkastning, kvalme og forstoppelse.
The most common side effects (may affect up to 1 in 10 people) are vomiting, nausea and constipation.
De mest almindelige bivirkninger (påvirker mere end 1 ud af 10 personer) hos patienter, der ikke er i dialyse, har også at gøre med maven eller tarmen:
The most common side effects (affecting more than 1 in 10 people) in patients not on dialysis also concern the stomach or bowel:
De mest almindelige bivirkninger (som kan forekomme i forbindelse med mere end 1 ud af 10 doser af vaccinen) er:
The most common side effects (these may occur with more than 1 in 10 doses of the vaccine) are:
De mest almindelige bivirkninger (≥ 10 %) var akatisi og somnolens, som var dosisrelaterede op til 111 mg.
The most common adverse drug reactions (ADRs) (≥ 10%) were akathisia and somnolence, which were dose-related up to 111 mg daily.
De mest almindelige bivirkninger (≥ 20 %) ved trametinib omfatter udslæt, diarré, træthed, perifert ødem, kvalme og akneiform dermatitis.
The most common adverse reactions (≥20%) for trametinib include rash, diarrhoea, fatigue, oedema peripheral, nausea, and dermatitis acneiform.
De mest almindelige bivirkninger (≥ 3% i puljede fase-3 studier), der forekom hos de patienter, der fik Zerbaxa, var kvalme, hovedpine, obstipation, diarré og pyreksi, og sværhedsgraden var generelt let eller moderat.
The most common adverse reactions (≥ 3% in pooled Phase 3 trials) occurring in patients receiving Zerbaxa were nausea, headache, constipation, diarrhoea, and pyrexia and were generally mild or moderate in severity.
De mest almindelige bivirkninger (≥ 35 %), som fremkom under behandling med Dacogen, er pyreksi, anæmi og trombocytopeni.
The most common adverse drug reactions (≥ 35%) reported during treatment with Dacogen are pyrexia, anaemia and thrombocytopaenia.
De mest almindelige bivirkninger af docetaxel givet alene er: Fald i antallet af røde og hvide blodlegemer, hårtab, kvalme, opkastning, sår i munden, diarré og træthed.
The most commonly reported adverse reactions of Docetaxel alone are: decrease in the number of red blood cells or white blood cells, alopecia, nausea, vomiting, sores in the mouth, diarrhoea and tiredness.
De mest almindelige bivirkninger af Docetaxel Winthrop givet alene er: Fald i antallet af røde og hvide blodlegemer, hårtab, kvalme, opkastning, sår i munden, diarré og træthed.
The most commonly reported adverse reactions of Docetaxel Winthrop alone are: decrease in the number of red blood cells or white blood cells, alopecia, nausea, vomiting, sores in the mouth, diarrhoea and tiredness.
De mest almindelige bivirkninger af TAXOTERE givet alene er: Fald i antallet af røde og hvide blodlegemer, hårtab, kvalme, opkastning, sår i munden, diarré og træthed.
The most commonly reported adverse reactions of TAXOTERE alone are: decrease in the number of red blood cells or white blood cells, alopecia, nausea, vomiting, sores in the mouth, diarrhoea and tiredness.
De mest almindelige bivirkninger der er observeret (hos 1 % til 10 % af patienterne) i forbindelse med Dynepo er: en stigning i blodtrykket.
The most frequent side effects observed (in 1% to 10% of patients) with Dynepo are: increase in blood pressure.
De mest almindelige bivirkninger er anført under punkt 4.8. Disse symptomer er generelt lette til moderate, for nogle patienter kan de dog være svære i intensitet.
The most commonly reported reactions are listed in section 4.8. Generally these symptoms are mild to moderate, however, in some patients they may be severe in intensity.
De mest almindelige bivirkninger er svimmelhed, sensoriske forstyrrelser (inklusive paræstesi), søvnforstyrrelser (inklusive søvnløshed og intense drømme), opstemthed eller angst, kvalme og/eller opkastning, rysten, hovedpine, irritabilitet, diaré, hyperhidrosis og vertigo.
Dizziness, sensory disturbances (including paraesthesia), sleep disturbances (including insomnia and intense dreams), agitation or anxiety, nausea and/or vomiting, tremor, headache, irritability, diarrhoea, hyperhydrosis and vertigo are the most commonly reported reactions.
De mest almindelige bivirkninger er svimmelhed, sensoriske forstyrrelser (inklusive paræstesier og følelsen af elektriske stød, især i hovedet), søvnforstyrrelser (inklusive søvnløshed og intense drømme), træthed, søvnighed, opstemthed eller angst, kvalme og/eller opkastning, rysten, hovedpine, myalgi, irritabilitet, diaré, hyperhidrosis og vertigo.
Dizziness, sensory disturbances (including paraesthesia or electric shock-like sensations, particularly in the head), sleep disturbances (including insomnia and intense dreams), fatigue, somnolence, agitation or anxiety, nausea and/or vomiting, tremor, headache, myalgia, irritability, diarrhoea, hyperhydrosis and vertigo are the most commonly reported reactions.
De mest almindelige bivirkninger er symptomer på lavt blodsukker (hypoglykæmi), som normalt er lette.
The most common side effects are symptoms of low blood sugar (hypoglycaemia), which are usually mild.
De mest almindelige bivirkninger for Targretin (observeres hos mere end 1 ud af 10 patienter) er leukopeni (nedsat antal hvide blodceller), hypotyroidisme (nedsat skjoldbruskkirtelfunktion), hyperlipæmi (forhøjede koncentrationer af fedt i blodet), hyperkolesterolæmi (forhøjet kolesteroltal), eksfoliativ dermatitis (hudafskalning), pruritus (kløe), udslæt, smerter, hovedpine og asteni (slaphed).
The most common side effects seen with Targretin (in more than 1 patient in 10) are leucopenia (reduced white cell count), hypothyroidism (underactive thyroid gland), hyperlipaemia (high levels of fats in the blood), hypercholesterolaemia (high blood cholesterol), exfoliative dermatitis (skin peeling), pruritus (itching), rash, pain, headache and asthenia (weakness).
De mest almindelige bivirkninger I pædiatriske ITP patienter i alderen 1 år og ældre (≥ 3 % og større end placebo) var øvre luftvejsinfektion, nasofaryngitis, hoste, diarré, pyreksi, rhinit, mavesmerter, orofaryngeale smerter, tandpine, udslæt, forhøjet AST og rinorré.
The most common adverse reactions in paediatric ITP patients 1 year and older (≥ 3% and greater than placebo) were upper respiratory tract infection, nasopharyngitis, cough, diarrhoea, pyrexia, rhinitis, abdominal pain, oropharyngeal pain, toothache, rash, increased AST and rhinorrhoea.
De mest almindelige bivirkninger med Diacomit (set hos over 1 ud af 10 patienter) er anoreksi, vægttab, søvnbesvær, døsighed, ataksi, hypotoni og dystoni.
The most common side effects with Diacomit (seen in more than 1 in 10 patients) are anorexia, weight loss, insomnia, drowsiness, ataxia, hypotonia and dystonia.
De mest almindelige bivirkninger var kvalme og svimmelhed.
The most common adverse reactions were nausea and dizziness.
De mest almindelige bivirkninger var lokale reaktioner ved injektionsstedet, symptomer fra de øvre luftveje og pruritus.
Most common adverse reactions were local injection site reactions, upper respiratory tract signs and symptoms, and pruritus.
De mest almindelige bivirkninger var øjensmerter (19,2 %), øjenirritation (17,8 %), lakrimation (6,4 %), okular hyperæmi (5,5 %) ogerytem i øjenlåg (1,7 %), som sædvanligvis var midlertidige og forekom ved inddrypning.
The most common adverse reactions were eye pain (19.2%), eye irritation (17.8%), lacrimation (6. 4%), ocular hyperaemia (5.5%) and eyelid erythema (1.7%) which were usually transitory and occurred during instillation.
De mest almindelige bivirkninger ved Ammonaps (som ses hos flere end 1 ud af 10 patienter) er udeblivende menstruation og uregelmæssig menstruation, men disse bivirkninger optræder kun hos kvinder i den fødedygtige alder.
The most common side effects with Ammonaps (seen in more than 1 patient in 10) are amenorrhoea (absence of periods) and irregular menstruation (irregular periods), but these only occur in fertile female patients.
De mest almindelige bivirkninger ved Atripla (som ses hos flere end 1 ud af 10 patienter) er svimmelhed, hovedpine, diarré, kvalme, opkast, udslæt, kraftesløshed, hypofosfatæmi (for lavt fosfatindhold i blodet) og forhøjet indhold i blodet af kreatinkinase (et enzym, der findes i musklerne).
The most common side effects with Atripla (seen in more than 1 patient in 10) are dizziness, headache, diarrhoea, nausea (feeling sick), vomiting, rash, asthenia (weakness), hypophosphataemia (low blood levels of phosphates) and elevated levels of creatine kinase (an enzyme found in muscles).
De mest almindelige bivirkninger ved Celsentri (der ses hos mellem 1 og 10 patienter ud af 100) er kvalme, diarré, træthed og hovedpine.
The most common side effects with Celsentri (seen in between one and 10 patient in 100) are nausea (feeling sick), diarrhoea, fatigue (tiredness) and headache.
De mest almindelige bivirkninger ved Combivir (set hos flere end 1 ud af 10 patienter) er diarré og kvalme.
The most common side effects when taking Combivir (seen in more than 1 patient in 10) are diarrhoea and nausea (feeling sick).
De mest almindelige bivirkninger ved Faslodex (som ses hos flere end 1 ud af 10 patienter) er kvalme, kraftesløshed, reaktioner på injektionsstedet (smerte eller inflammation) og forhøjet antal leverenzymer i blodet.
The most common side effects with Faslodex (seen in more than 1 patient in 10) are nausea (feeling sick), asthenia (weakness), injection-site reactions (such as pain or inflammation) and increased liver enzyme levels in the blood.
De mest almindelige bivirkninger ved Imbruvica (der kan forekomme hos 1 ud af 5 personer) er diarré, neutropeni (lavt antal hvide blodlegemer af typen neutrofile), muskuloskeletale smerter (smerter i muskler og knogler), blødning, blå mærker, udslæt, kvalme og feber.
The most common side effects with Imbruvica (which may affect more than 1 in 5 people) are diarrhoea, neutropenia (low levels of neutrophils, a type of white blood cell), musculoskeletal pain (pain in muscles and bones), haemorrhage (bleeding), bruising, rash, nausea (feeling sick) and fever.
De mest almindelige bivirkninger ved intravenøse infusioner med MabThera er reaktioner i forbindelse med infusionen (f.eks. feber, kuldegysninger og kulderystelser), og de mest almindelige alvorlige bivirkninger er reaktioner på infusionen, infektioner og hjerteproblemer.
The most common side effects with Mabthera intravenous infusions are reactions related to the infusion (such as fever, chills and shivering) while most common serious side effects are infusion reactions, infections and heart-related problems.
De mest almindelige bivirkninger ved Myocet (som optræder hos flere end 1 ud af 10 patienter) er feber i forbindelse med et meget lavt antal neutrofiler (en type hvide blodlegemer), infektion, neutropeni (lavt antal neutrofiler, thrombocytopeni (lavt antal blodplader), anæmi (lavt antal røde blodlegemer), leukopeni (lavt antal hvide blodlegemer), appetitløshed, kvalme eller opkast, betændelse i mundslimhinden, diarré, hårtab, kraftesløshed, feber, smerter og kulderystelser.
The most common side effects with Myocet (seen in more than 1 patient in 10) are neutropenic fever (fever associated with low levels of neutrophils, a type of white blood cell), infection, neutropenia (low levels of neutrophils), thrombocytopenia (low blood platelet counts), anaemia (low red blood cell counts), leucopenia (low white blood cell counts), loss of appetite, nausea (feeling sick) or vomiting, stomatitis (inflammation of the lining of the mouth) or mucositis (inflammation of the moist body surfaces), diarrhoea, alopecia (hair loss), asthenia (weakness), fever, pain and rigors (shaking chills).
De mest almindelige bivirkninger ved Onivyde (der kan forekomme hos mere end 1 ud af 5 patienter) er diarré, kvalme, opkastning, nedsat appetit, lavt antal hvide blodlegemer (neutropeni), træthed, svaghed, lavt antal røde blodlegemer (anæmi), mundbetændelse (stomatitis) og feber.
The most common side effects with Onivyde (which may affect more than 1 in 5 people) are diarrhoea, nausea (feeling sick), vomiting, loss of appetite, neutropenia (low levels of neutrophils, a type of white blood cell), tiredness, weakness, anaemia (low red blood cell counts) stomatitis (inflammation of the lining of the mouth) and fever.
De mest almindelige bivirkninger ved Pandemisk influenzavaccine H5N1 MedImmune (som kan forekomme hos mere end 1 ud af 10 personer) er nedsat appetit, hovedpine, løbende eller stoppet næse og utilpashed.
The most common side effects with Pandemic influenza vaccine H5N1 MedImmune (which may affect more than 1 in 10 people) are decreased appetite, headache, runny or stuffy nose, and feeling unwell.
De mest almindelige bivirkninger ved saxagliptin anvendt sammen med metformin (som optræder hos mellem 1 og 10 patienter ud af 100) er infektioner i de øvre luftveje (forkølelse), urinvejslidelser (infektion i de strukturer i kroppen, som leder urinen, som f.eks. blæren), gastroenteritis (diarré og opkastning), bihulebetændelse (infektion af bihulerne), nasofaryngitis (infektion af næse og hals), hovedpine og opkastning.
The most common side effects seen with saxagliptin used together with metformin (seen in between 1 and 10 patients in 100) are upper respiratory infection (cold), urinary tract infection (infection of the structures that carry urine such as the bladder), gastroenteritis (diarrhoea and vomiting), sinusitis (inflammation of the sinuses), nasopharyngitis (inflammation of the nose and throat), headache and vomiting.
De mest almindelige bivirkninger ved tabletterne og opløsningen til injektion er mild og forbigående påvirkning af mave- og tarmkanalen, der ses som opkastning, blød afføring og diarré.
The most common side effects of the tablets and solution for injection are mild and transient effects on the stomach and gut, seen as vomiting, soft faeces and diarrhoea.
De mest almindelige bivirkninger ved Xeloda (der ses hos flere end 1 ud af 10 patienter) er appetitløshed, diarré, opkastning, kvalme, mundsår, mavesmerter, "hånd-fod syndrom" (palmar- plantar erytrodysæstesi-syndrom, en hudreaktion med udslæt og smerte på hænder og fødder), træthed og svaghed.
The most common side effects with Xeloda (seen in more than 1 patient in 10) are anorexia (loss of appetite), diarrhoea, vomiting, nausea (feeling sick), stomatitis (sores in the mouth), abdominal (tummy) pain, palmar-plantar erythrodysaesthesia syndrome (‘hand-foot syndrome’, a skin reaction with rash and pain on the hands and feet), fatigue (tiredness) and asthenia (weakness).
De mest almindelige bivirkninger ved Zerene (som ses hos mellem 1 og 10 patienter ud af 100) er hukommelsesproblemer (amnesi), usædvanlige følefornemmelser som f.eks. prikken og stikken (paræstesi), søvnighed (somnolens), og stærke, smertefulde kramper under menstruation (dysmenoré).
The most common side effects with Zerene (seen in between 1 and 10 patients in 100) are amnesia (memory problems), paraesthesia (unusual sensations like pins and needles), somnolence (sleepiness) and dysmenorrhoea (painful menstruation).
De mest almindelige bivirkninger, der blev anset for at være relateret til administration af MabThera, var infusionsrelaterede reaktioner.
The most frequent adverse reactions considered due to receipt of MabThera IRRs.
De mest almindelige bivirkninger, der er indberettet ved brug af M-M-RVAXPRO, var feber (38,5 °C eller derover), reaktioner på injektionsstedet, herunder smerter, hævelse og erytem.
The most common adverse reactions reported with the use of M-M-RVAXPRO were: fever (38.5°C or higher); injection site reactions including pain, swelling and erythema.